GlaxoSmithKline für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 940561 / ISIN: GB0009252882

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu GlaxoSmithKline plc (GSK)

07:00		GSK and Fleming Initiative scientists unite to target AMR with advanced AI (EN, GlaxoSmithKline)
07.11.25		GSK presents data from its advancing liver pipeline at AASLD 2025 (EN, GlaxoSmithKline)
29.10.25		GSK delivers strong Q3 performance and upgrades 2025 guidance (EN, GlaxoSmithKline)
28.10.25		GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases (EN, GlaxoSmithKline)
28.10.25		GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU (EN, GlaxoSmithKline)
27.10.25		GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer (EN, GlaxoSmithKline)
23.10.25		Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
22.10.25		GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler (EN, GlaxoSmithKline)
21.10.25		GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion (EN, GlaxoSmithKline)
21.10.25		Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs) (EN, GlaxoSmithKline)
20.10.25		Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment (EN, GlaxoSmithKline)
15.10.25		ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir (EN, GlaxoSmithKline)
14.10.25		GSK’s Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression (EN, GlaxoSmithKline)
29.09.25		Luke Miels appointed CEO designate for GSK (EN, GlaxoSmithKline)
22.09.25		GSK to submit label update for Wellcovorin (leucovorin) at US FDA’s request (EN, GlaxoSmithKline)
17.09.25		GSK to invest $30 billion in R&D and Manufacturing in the United States over next 5 years (EN, GlaxoSmithKline)
15.09.25		GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society (ERS) Congress 2025 (EN, GlaxoSmithKline)
11.08.25		Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea (EN, GlaxoSmithKline)
08.08.25		GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation (EN, GlaxoSmithKline)
30.07.25		GSK delivers continued strong performance (EN, GlaxoSmithKline)
29.07.25		GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation (EN, GlaxoSmithKline)
28.07.25		GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology (EN, GlaxoSmithKline)
24.07.25		Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
23.07.25		GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
17.07.25		GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
17.07.25		US FDA approves GSK’s Shingrix in a prefilled syringe presentation (EN, GlaxoSmithKline)
14.07.25		US FDA accepts application to review expanded use of GSK’s RSV vaccine, Arexvy, for adults 18-49 at increased risk (EN, GlaxoSmithKline)
08.07.25		ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025 (EN, GlaxoSmithKline)
07.07.25		GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) (EN, GlaxoSmithKline)
25.06.25		Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5 (EN, GlaxoSmithKline)
23.06.25		Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
20.06.25		Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease (EN, GlaxoSmithKline)
13.06.25		GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older (EN, GlaxoSmithKline)
12.06.25		GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development (EN, GlaxoSmithKline)
02.06.25		Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
29.05.25		GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio (EN, GlaxoSmithKline)
28.05.25		PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee (EN, GlaxoSmithKline)
23.05.25		Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
21.05.25		Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) (EN, GlaxoSmithKline)
19.05.25		Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
14.05.25		GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) (EN, GlaxoSmithKline)
13.05.25		GSK provides update on belrestotug development programme (EN, GlaxoSmithKline)
08.05.25		GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
02.05.25		GSK continues to advance the future of respiratory medicine and patient care with new data at ATS (EN, GlaxoSmithKline)
30.04.25		Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine (EN, GlaxoSmithKline)
30.04.25		GSK makes strong start to 2025 with growth in sales, profits and earnings (EN, GlaxoSmithKline)
17.04.25		Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
16.04.25		GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices (EN, GlaxoSmithKline)
25.03.25		Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older (EN, GlaxoSmithKline)
25.03.25		GSK, UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to collaborate on first-of-its-kind dementia research initiative (EN, GlaxoSmithKline)

1 | Weiter

Newssuche

GlaxoSmithKline Peer Group Nachrichten

22.11.23		GSK-Aktie tiefer: Jefferies senkt Kursziel für GlaxoSmithKline
01.06.22		IPO: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer will aussteigen
31.05.22		GSK-Aktie kaum fester: GlaxoSmithKline übernimmt Biopharma-Spezialisten in Milliardendeal
28.02.22		GlaxoSmithKline-Aktie tiefer: GSK will Haleon an die Börse bringen - GlaxoSmithKline stellt Tests für ein Vakzin gegen RSV ein
09.02.22		GSK-Aktie gibt dennoch nach: GlaxoSmithKline verdient im Schlussquartal deutlich mehr

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	18.11.2025 17:51
Kaufwert:	EUR
	Hinzufügen Speichern

GlaxoSmithKline Aktie

WKN: 940561 / ISIN: GB0009252882

Nachrichten zu GlaxoSmithKline plc (GSK)

Newssuche

GlaxoSmithKline Peer Group Nachrichten

Meistgelesene Nachrichten